Recent Advances in Meningioma Immunogenetics

May Al-Rashed; Kara Foshay; Malak Abedalthagafi

doi:10.3389/fonc.2019.01472

Recent Advances in Meningioma Immunogenetics

Front Oncol. 2020 Jan 8:9:1472. doi: 10.3389/fonc.2019.01472. eCollection 2019.

Authors

May Al-Rashed¹, Kara Foshay^{2

3}, Malak Abedalthagafi⁴

Affiliations

¹ Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
² Inova Neuroscience and Spine Institute, Inova Health Systems, Falls Church, VA, United States.
³ Virginia Commonwealth University School of Medicine, Inova Campus, Richmond, VA, United States.
⁴ Genomics Research Department, Saudi Human Genome Project, King Fahad Medical City, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia.

Abstract

Meningiomas are relatively common, and typically benign intracranial tumors, which in many cases can be cured by surgical resection. However, less prevalent, high grade meningiomas, grow quickly, and recur frequently despite treatment, leading to poor patient outcomes. Across tumor grades, subjective guidelines for histological analysis can preclude accurate diagnosis, and an insufficient understanding of recurrence risk can cloud the choice of optimal treatment. Improved diagnostic and prognostic markers capable of discerning between the 15 heterogeneous WHO recognized meningioma subtypes are necessary to improve disease management and identify new targeted drug treatments. In this review, we show the advances in molecular profiling and immunophenotyping of meningiomas, which may lead to the development of new personalized therapeutic strategies.

Keywords: NGS; genomics; immunotherapy; meningioma; neuro-oncology; personalized medicine.

Publication types

Review